Recombinant Human Activin RIIB Fc Chimera (Sf 21), CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Activin RIIB Fc Chimera (Sf 21), CF Summary

• Details of Functionality: Measured by its ability to inhibit Activin A-induced hemoglobin expression in K562 human chronic myelogenous leukemia cells. Schwall, R.H. et al. (1991) Method Enzymol. 198:340. Approximately 0.02-0.06 µg/mL of rhActivin RIIB/Fc Chimera will inhibit 50% of the biological response due to 3 ng/mL of rhActivin A.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Activin RIIB protein
  

  Met	Human Activin RIIB (Ser19 - Thr 134) Accession # CAA54671.1	IEGRMD	Human IgG1 (Pro100 - Lys330)	6-His tag
  N-terminus				C-terminus

• Accession #: CAA54671.1
• N-terminal Sequence: Met
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: ACVR2B
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.1 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 41 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Activin RIIB Fc Chimera (Sf 21), CF

• activin A receptor, type IIB
• Activin receptor type IIB
• activin receptor type-2B
• Activin RIIB
• ActivinRIIB
• ACTRIIB
• ActR-IIB
• ACVR2B
• EC 2.7.11
• EC 2.7.11.30
• MGC116908

Background

Activin isoforms and other members of the TGF-beta  superfamily exert their biological effects by binding to heteromeric complexes of a type I and a type II serine-threonine kinase receptor, both of which are essential for signal transduction. To date, seven type I and five type II receptors, including the two type I and the two type II activin receptors, designated ActR-I(A), ActR-IB, ActR-II(A) and ActR-IIB, have been cloned from mammals. Through alternative mRNA splicing, multiple ActR-IIB isoforms can also be generated, adding to the complexity of the activin receptor system. Different activin isoforms bind with different high-affinities to the various type II isoforms. Type I activin receptors do not bind directly to activin, but will associate with the type II receptor-activin complex and initiate signal transduction. Besides the activin isoforms, ActR-II will also bind inhibin, BMP-2 and BMP-7 with lower affinities. ActR-I can also bind and form signaling complexes with the BMP-2/7-bound BMPR-II. Activin type II receptors are highly conserved. Human, mouse and rat type II activin receptors share greater than 98% amino acid sequence homology. Recombinant soluble activin type II receptors bind activin with high affinity, and are potent activin antagonists.

1. Attisano, L. et al. (1996) Mol. and Cell Biol. 16:1066.
2. Woodruff, T.K. (1998) Biochem. Pharmacology 55:953.

Bioinformatics

• Gene Symbol: ACVR2B
• Uniprot:
  • CAA54671.1()